These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35901359)

  • 1. Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2022 Jul; 23(7):2497-2505. PubMed ID: 35901359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
    Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
    Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.
    Murray NP; Villalon R; Aedo S; Hartmann D; Rodriguez MP
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3373-3379. PubMed ID: 37898840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of matrix-metalloproteinase-2 in bone marrow micro-metastasis is associated with the presence of circulating prostate cells and a worse prognosis in men treated with radical prostatectomy for prostate cancer.
    Murray NP; Reyes E; Salazar A; Lopez MA; Orrego S; Guzman E
    Turk J Urol; 2020 May; 46(3):186-195. PubMed ID: 32401703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CAPRA-S Score and Immune Dysfunction as a Guide to Outcome in Men Treated with Prostatectomy Radical as Mono-Therapy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Arch Esp Urol; 2022 Aug; 75(6):507-516. PubMed ID: 36138499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Bádinez L; Olivares R; Porcell J; Dueñas R
    ScientificWorldJournal; 2013; 2013():762064. PubMed ID: 23653529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of androgen blockade on HER-2 and matrix metalloproteinase-2 expression on bone marrow micrometastasis and stromal cells in men with prostate cancer.
    Murray NP; Reyes E; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R
    ScientificWorldJournal; 2013; 2013():281291. PubMed ID: 23766685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining the Prostate Cancer Risk Index (PRIX) with the Presence of Secondary Circulating Prostate Cells to Predict the Risk of Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Jacob O
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3375-3381. PubMed ID: 30583343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redefining micrometastasis in prostate cancer - a comparison of circulating prostate cells, bone marrow disseminated tumor cells and micrometastasis: Implications in determining local or systemic treatment for biochemical failure after radical prostatectomy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Porcell J; Dueñas R
    Int J Mol Med; 2012 Oct; 30(4):896-904. PubMed ID: 22825050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of primary circulating prostate cells after radical prostatectomy for prostate cancer decreases the risk of future biochemical failure.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Dueñas R
    Arch Esp Urol; 2014 Oct; 67(8):684-91. PubMed ID: 25306986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between Use of PSA Kinetics and Bone Marrow Micrometastasis to Define Local or Systemic Relapse in Men with Biochemical Failure after Radical Prostatectomy for Prostate Cancer.
    Murray NP; Reyes E; Fuentealba C; Orellana N; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(18):8387-90. PubMed ID: 26745090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10 Year Biochemical Failure Free Survival of Men with CD82 Positive Primary Circulating Prostate Cells Treated by Radical Prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E
    Asian Pac J Cancer Prev; 2018 Jun; 19(6):1577-1583. PubMed ID: 29936782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [CAPRA score vs minimal residual disease as predictors of biochemical recurrence after radical prostatectomy.].
    Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
    Arch Esp Urol; 2021 Jul; 74(6):554-563. PubMed ID: 34219057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
    Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Walz Nomogram and Presence of Secondary Circulating Prostate Cells for Predicting Early Biochemical Failure after Radical Prostatectomy for Prostate Cancer in Chilean Men.
    Murray NP; Reyes E; Orellana N; Fuentealba C; Jacob O
    Asian Pac J Cancer Prev; 2015; 16(16):7123-7. PubMed ID: 26514500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
    Chalfin HJ; Glavaris SA; Malihi PD; Sperger JM; Gorin MA; Lu C; Goodwin CR; Chen Y; Caruso EA; Dumpit R; Kuhn P; Lang JM; Nelson PS; Luo J; Pienta KJ
    J Urol; 2018 Jun; 199(6):1494-1501. PubMed ID: 29339080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
    Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
    Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.